Aprea Therapeutics
APRE
39 hedge funds and large institutions have $25.6M invested in Aprea Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 17 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.36% less ownership
Funds ownership: 1.54% → 1.18% (-0.36%)
19% less capital invested
Capital invested by funds: $31.4M → $25.6M (-$5.87M)
22% less funds holding
Funds holding: 50 → 39 (-11)
61% less call options, than puts
Call options by funds: $599K | Put options by funds: $1.53M
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$575K |
| 2 |
JP Morgan Chase
New York
|
+$571K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$426K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$424K |
| 5 |
Goldman Sachs
New York
|
+$373K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.79M |
| 2 |
SG Americas Securities
New York
|
-$2.92M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$743K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$470K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$461K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GLA
51
Great Lakes Advisors
Chicago,
Illinois
| – | -$87K | -895 | Closed |
|
|
TSS
52
Two Sigma Securities
New York
| – | -$58K | -598 | Closed |
|
|
HTC
53
Hershey Trust Company
Hershey,
Pennsylvania
| – | -$48K | -491 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$6K | -66 | Closed |
|
APRE Hedge Fund Activity: Q3 2021 in Review
39 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2021, worth a combined $25.6M — down 19% from $31.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of APRE and 6 opened new positions — a net loss of 11 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Susquehanna International Group, adding an estimated $575K. The largest seller was Morgan Stanley, cutting an estimated $3.79M.
- 39 institutional investors held Aprea Therapeutics (APRE) as of Q3 2021, down from 50 in Q2 2021.
- Funds reported $25.6M of Aprea Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
- 6 funds opened new Aprea Therapeutics positions in Q3 2021 and 17 closed out, a net change of -11 holders.
- The largest Aprea Therapeutics buyer in Q3 2021 was Susquehanna International Group, an estimated $575K added.
- The largest Aprea Therapeutics seller in Q3 2021 was Morgan Stanley, an estimated $3.79M sold.
Based on aggregated 13F filings for Q3 2021.